Skip to content

Study · Observational study · n = 50 · 2017

2 results

Efficacy of Cerebrolysin in the reduction of spasticity during stroke rehabilitation.

Martinez RM

Journal of medicine and life1 Jul 2017Cited by 8 (Europe PMC)

PMID29075344 (opens in a new tab)PMCIDPMC5652267 (opens in a new tab)PepBankPUB-29075344
Download PDFPubMedAsk about this study
Jump to 2 results

Summary

AimThis study assessed the efficacy of Cerebrolysin on post-stroke spasticity, motor recovery, and global functions in an outpatient rehabilitation setting.MethodsIn this retrospective comparison study, Cerebrolysin was administered at a daily dosage of 10 ml for over 30 days as an intramuscular injection. Control patients did not receive Cerebrolysin. All the patients participated in a standardized physical and occupational rehabilitation therapy for one month at least two times per week. Efficacy was assessed at day 30 by using the Modified Ashworth Scale (MAS) for spasticity and the Manual Muscle Testing (MMT) for motor recovery. Global function was assessed by the modified Rankin Scale (mRS) at day 30.ResultsA total of 50 patients were eligible for participation according to the inclusion and exclusion criteria. Of these, 23 patients were treated with Cerebrolysin and 27 patients represented the control group. No significant group differences were observed at baseline. Patients treated with Cerebrolysin experienced a significant reduction of spasticity in muscles of the upper and lower limbs, whereas only minor changes were observed in the control group. In the Cerebrolysin group, differences were statistically significant at day 30. Significant improvements of muscle strength and global functions were observed in both groups at day 30. Cerebrolysin was safe and well tolerated.ConclusionCerebrolysin had a beneficial effect on post-stroke spasticity in an outpatient rehabilitation setting; intramuscular treatment for over 30 days was safe and well tolerated.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In stroke rehabilitation patients, Cerebrolysin was linked to reduced upper and lower limb spasticity, while controls showed only minor changes.

    In plain wordsIn stroke rehabilitation patients, Cerebrolysin was linked to less limb spasticity, while controls showed only minor changes.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseLimb spasticity
    Study

    n = 50

    Comparator
    Patients without Cerebrolysin
    Outcome group
    Exercise and physical function · Nervous system and cognition
    Studied dose
    10 ml daily · intramuscular injection · over 30 daysAs given in this study (human).

    Source sentences

    Summary
    Patients treated with Cerebrolysin experienced a significant reduction of spasticity in muscles of the upper and lower limbs, whereas only minor changes were observed in the control group.
    2 context sentences
    Summary · context
    In this retrospective comparison study, Cerebrolysin was administered at a daily dosage of 10 ml for over 30 days as an intramuscular injection.
    Summary · context
    Control patients did not receive Cerebrolysin.
  2. 02HumanObservational studySafety outcome

    In stroke rehabilitation patients, Cerebrolysin was safe and well tolerated.

    In plain wordsIn stroke rehabilitation patients, Cerebrolysin was safe and well tolerated.

    Peptide
    Cerebrolysin
    Outcome
    Not applicableSafety and tolerability
    Study

    n = 23

    Outcome group
    Adverse events · Whole body
    Studied dose
    10 ml daily · intramuscular injection · over 30 daysAs given in this study (human).

    Source sentences

    Summary
    Cerebrolysin was safe and well tolerated.
    2 context sentences
    Summary · context
    In this retrospective comparison study, Cerebrolysin was administered at a daily dosage of 10 ml for over 30 days as an intramuscular injection.
    Summary · context
    Control patients did not receive Cerebrolysin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.